US-based firm Ampersand Capital Partners has acquired a 33.3% stake in Netherlands-based diagnostics firm Genome Diagnostics (GenDX).
GP said the deal will facilitate further investment in the development of Nordic Capital
KKR, Index Ventures, Ares and Alven Capital have each sold 50% of their shares in the company
In his new role, Piacentini will support KKR's technology, media and telecoms investment activities
Transaction sees the management team retain a majority stake in consultancy Epsa